Tirzepatide: a dual peptide for weight control — how it works
Tirzepatide is a dual agonist of the GLP-1 and GIP receptors. Clinical data show weight loss of up to 22.5%. Learn about the mechanism, dosing, and what the studies show.
Peptolux Labs
When Semaglutide changed our understanding of weight-loss peptides, the question was — could something be even more effective? The answer came in the form of Tirzepatide, a molecule that acts not through one, but through two mechanisms simultaneously.
Tirzepatide is the active ingredient behind Mounjaro and Zepbound. Instead of stimulating only one hormone, it activates both the GLP-1 and GIP receptors simultaneously. The result: a stronger effect on appetite, metabolism, and blood sugar control.
What is Tirzepatide?
Tirzepatide is a synthetic peptide of 39 amino acids, created as a dual agonist of two incretin receptors: GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide). These two hormones are naturally produced in the gut after eating and play a key role in metabolism.
Unlike Semaglutide, which acts only on GLP-1, Tirzepatide is designed to activate both receptors. It is the first FDA-approved dual incretin agonist in the world.
How does Tirzepatide work?
Tirzepatide's dual mechanism means the body receives signals from two different systems simultaneously:
- GLP-1 activation: reduces appetite, slows gastric emptying, improves insulin secretion
- GIP activation: improves fat metabolism, increases insulin sensitivity in adipose tissue, improves the lipid profile
- Suppresses glucagon secretion — stabilizes blood sugar and reduces hunger episodes
- Improves glucose uptake in muscles and adipose tissue
- Reduces systemic inflammation associated with obesity
Synergistic effect: the two mechanisms don't simply add up — they reinforce each other. The GIP receptor in adipose tissue improves fat metabolism, while GLP-1 controls appetite. The result is greater weight loss than either mechanism alone.
What do the studies show?
Tirzepatide has been studied in the large-scale SURMOUNT program involving thousands of participants. The data has been published in the New England Journal of Medicine and other leading journals.
- SURMOUNT-1: average weight loss of 22.5% at the highest dose (15 mg) over 72 weeks
- SURMOUNT-2 (in patients with type 2 diabetes): 14.7% weight loss and significant improvement in HbA1c
- Over 60% of participants achieved a weight loss of 20%+ of their body weight
- Improvement in blood pressure, triglycerides, and cholesterol
- The effect is maintained with continued use
Comparison with Semaglutide: in head-to-head trials, Tirzepatide shows 5-7% greater weight loss compared to Semaglutide at equivalent doses. The dual mechanism provides a measurable advantage.
How is it taken?
Tirzepatide is administered as a subcutaneous injection once weekly. The schedule includes gradual titration to minimize side effects:
- Weeks 1-4: 2.5 mg once weekly (starting dose)
- Weeks 5-8: 5 mg once weekly
- Weeks 9-12: 7.5 mg once weekly
- Weeks 13-16: 10 mg once weekly
- Weeks 17+: 12.5-15 mg once weekly (maximum dose)
It is injected subcutaneously into the abdomen, thigh, or upper arm. The injection day can be any day, as long as it is the same day each week. It is not necessary to inject on an empty stomach.
Side effects
The most common side effects are gastrointestinal and generally decrease over time:
- Nausea — most common at the start and when increasing the dose (resolves within 1-2 weeks)
- Diarrhea or constipation — usually mild and temporary
- Reduced appetite — an expected effect, not a side effect in the traditional sense
- Abdominal pain — rare, at higher doses
- Fatigue — in the first days after injection, while the body adjusts
Slow titration is key: almost all stomach complaints are due to increasing the dose too quickly. Following the 4-week intervals minimizes discomfort.
Frequently asked questions
What is the difference between Tirzepatide and Semaglutide?
Semaglutide acts only on the GLP-1 receptor, while Tirzepatide is a dual agonist (GLP-1 + GIP). This provides a stronger effect on weight and metabolism. In clinical trials, Tirzepatide shows 5-7% greater weight loss.
How quickly are results seen?
Most people notice reduced appetite as early as the first week. Weight loss is usually visible from week 4. The full effect is achieved over 6-9 months upon reaching the target dose.
Can it be combined with training?
Yes, strength training is recommended. It helps preserve muscle mass during weight loss. Adequate protein intake (1.6-2.0 g/kg) is also important.
How is it stored?
In a refrigerator (2-8°C) before reconstitution. After dissolving — in a refrigerator for up to 28 days. Do not freeze.
Important: This article is for informational purposes and does not constitute medical advice. Tirzepatide is intended for research use. Consult a physician before use.